B-Diagnostic_tool	0	7	Optical
I-Diagnostic_tool	8	17	coherence
I-Diagnostic_tool	18	28	tomography
O	28	29	-
O	29	34	based
O	35	46	observation
O	47	49	of
O	50	53	the
O	54	61	natural
O	62	69	history
O	70	72	of
B-Symptom	73	82	drusenoid
I-Symptom	83	89	lesion
O	90	92	in
B-Anatomy	93	97	eyes
O	98	102	with
B-Disease	103	106	dry
I-Disease	107	110	age
I-Disease	110	111	-
I-Disease	111	118	related
I-Disease	119	126	macular
I-Disease	127	139	degeneration
O	139	140	.

O	142	144	To
O	145	148	use
B-Diagnostic_tool	149	157	spectral
I-Diagnostic_tool	158	164	domain
I-Diagnostic_tool	165	172	optical
I-Diagnostic_tool	173	182	coherence
I-Diagnostic_tool	183	193	tomography
O	194	195	(
B-Diagnostic_tool	195	197	SD
I-Diagnostic_tool	197	198	-
I-Diagnostic_tool	198	201	OCT
O	201	202	)
O	203	205	to
O	206	217	investigate
O	218	222	risk
O	223	230	factors
O	231	241	predictive
O	242	245	for
O	246	249	the
O	250	261	development
O	262	264	of
B-Symptom	265	272	atrophy
I-Symptom	273	275	of
I-Symptom	276	285	drusenoid
I-Symptom	286	293	lesions
O	294	295	(
B-Symptom	295	298	DLs
O	298	299	)
O	300	301	(
B-Symptom	301	307	drusen
O	308	311	and
B-Symptom	312	321	drusenoid
I-Symptom	322	329	pigment
I-Symptom	330	340	epithelium
I-Symptom	341	351	detachment
O	351	352	)
O	353	355	in
B-Anatomy	356	360	eyes
O	361	365	with
B-Disease	366	369	non
I-Disease	369	370	-
I-Disease	370	381	neovascular
I-Disease	382	385	age
I-Disease	385	386	-
I-Disease	386	393	related
I-Disease	394	401	macular
I-Disease	402	414	degeneration
O	415	416	(
B-Disease	416	422	NNVAMD
O	422	423	)
O	423	424	.

O	425	431	Cohort
O	432	437	study
O	437	438	.

O	439	444	Forty
O	444	445	-
O	445	448	one
B-Anatomy	449	453	eyes
O	454	458	from
O	459	461	29
O	462	470	patients
O	471	475	with
B-Disease	476	482	NNVAMD
O	482	483	.

O	484	492	Patients
O	493	497	with
B-Disease	498	504	NNVAMD
O	505	508	who
O	509	518	underwent
O	519	529	registered
B-Diagnostic_tool	530	532	SD
I-Diagnostic_tool	532	533	-
I-Diagnostic_tool	533	536	OCT
I-Diagnostic_tool	537	544	imaging
O	545	549	over
O	550	551	a
O	552	559	minimum
O	560	566	period
O	567	569	of
O	570	571	6
O	572	578	months
O	579	583	were
O	584	592	reviewed
O	592	593	.

B-Symptom	594	603	Drusenoid
I-Symptom	604	611	lesions
O	612	616	that
O	617	621	were
O	622	633	accompanied
O	634	636	by
O	637	640	new
B-Symptom	641	648	atrophy
O	649	654	onset
O	655	657	at
O	658	659	6
O	660	666	months
O	667	669	or
O	670	674	last
O	675	681	follow
O	681	682	-
O	682	684	up
O	685	686	(
O	686	689	FUL
O	689	690	)
O	691	695	were
O	696	703	further
O	704	712	analyzed
O	712	713	.

O	714	722	Detailed
O	723	729	lesion
O	730	736	change
O	737	740	was
O	741	750	described
O	751	761	throughout
O	762	765	the
O	766	771	study
O	772	778	period
O	778	779	.

O	780	784	Odds
O	785	791	ratios
O	792	793	(
O	793	796	ORs
O	796	797	)
O	798	801	and
O	802	806	risk
O	807	810	for
O	811	814	new
B-Symptom	815	820	local
I-Symptom	821	828	atrophy
O	829	834	onset
O	835	839	were
O	840	850	calculated
O	850	851	.

B-Symptom	852	861	Drusenoid
I-Symptom	862	868	lesion
O	869	877	features
O	878	881	and
O	882	894	longitudinal
O	895	902	changes
O	903	905	in
O	906	914	features
O	914	915	,
O	916	925	including
B-Characteristic	926	933	maximum
I-Characteristic	934	940	lesion
I-Characteristic	941	947	height
O	947	948	,
B-Characteristic	949	955	lesion
I-Characteristic	956	964	diameter
O	964	965	,
B-Characteristic	966	972	lesion
I-Characteristic	973	981	internal
I-Characteristic	982	994	reflectivity
O	994	995	,
O	996	999	and
O	1000	1008	presence
O	1009	1012	and
O	1013	1019	extent
O	1020	1022	of
B-Symptom	1023	1032	overlying
I-Symptom	1033	1045	intraretinal
I-Symptom	1046	1061	hyperreflective
I-Symptom	1062	1066	foci
O	1067	1068	(
B-Symptom	1068	1071	HRF
O	1071	1072	)
O	1072	1073	.

B-Characteristic	1074	1083	Subfoveal
I-Characteristic	1084	1093	choroidal
I-Characteristic	1094	1103	thickness
O	1104	1105	(
B-Characteristic	1105	1109	SFCT
O	1109	1110	)
O	1111	1114	and
B-Characteristic	1115	1124	choroidal
I-Characteristic	1125	1134	thickness
O	1135	1136	(
B-Characteristic	1136	1138	CT
O	1138	1139	)
O	1140	1144	were
O	1145	1153	measured
O	1154	1159	below
O	1160	1164	each
O	1165	1171	lesion
O	1171	1172	.

O	1173	1174	A
O	1175	1180	total
O	1181	1183	of
O	1184	1187	543
O	1188	1198	individual
B-Symptom	1199	1202	DLs
O	1203	1207	were
O	1208	1218	identified
O	1219	1221	at
O	1222	1230	baseline
O	1230	1231	,
O	1232	1235	and
O	1236	1238	28
O	1239	1246	lesions
O	1247	1256	developed
O	1257	1263	during
O	1264	1270	follow
O	1270	1271	-
O	1271	1273	up
O	1273	1274	.

O	1275	1278	The
O	1279	1283	mean
O	1284	1290	follow
O	1290	1291	-
O	1291	1293	up
O	1294	1298	time
O	1299	1302	was
O	1303	1305	21
O	1305	1306	.
O	1306	1307	3
O	1307	1308	±
O	1308	1309	8
O	1309	1310	.
O	1310	1311	6
O	1312	1318	months
O	1319	1320	(
O	1320	1325	range
O	1325	1326	,
O	1327	1328	6
O	1328	1329	-
O	1329	1331	44
O	1332	1338	months
O	1338	1339	)
O	1339	1340	.

O	1341	1345	Some
O	1346	1347	3
O	1347	1348	.
O	1348	1349	2
O	1349	1350	%
O	1351	1353	of
B-Symptom	1354	1357	DLs
O	1358	1359	(
O	1359	1361	18
O	1361	1362	/
O	1362	1365	571
O	1365	1366	)
O	1367	1377	progressed
O	1378	1380	to
B-Symptom	1381	1388	atrophy
O	1389	1395	within
O	1396	1398	18
O	1398	1399	.
O	1399	1400	3
O	1401	1402	±
O	1403	1404	9
O	1404	1405	.
O	1405	1406	5
O	1407	1413	months
O	1414	1415	(
O	1415	1420	range
O	1420	1421	,
O	1422	1423	5
O	1423	1424	-
O	1424	1426	28
O	1427	1433	months
O	1433	1434	)
O	1435	1437	of
O	1438	1441	the
O	1442	1449	initial
O	1450	1455	visit
O	1455	1456	.

B-Symptom	1457	1466	Drusenoid
I-Symptom	1467	1474	lesions
I-Symptom	1475	1479	with
I-Symptom	1480	1493	heterogeneous
I-Symptom	1494	1502	internal
I-Symptom	1503	1515	reflectivity
O	1516	1520	were
O	1521	1534	significantly
O	1535	1545	associated
O	1546	1550	with
O	1551	1554	new
B-Symptom	1555	1562	atrophy
O	1563	1568	onset
O	1569	1571	at
O	1572	1573	6
O	1574	1580	months
O	1581	1582	(
O	1582	1584	OR
O	1584	1585	,
O	1586	1587	5
O	1587	1588	.
O	1588	1591	614
O	1591	1592	;
O	1593	1595	95
O	1595	1596	%
O	1597	1607	confidence
O	1608	1616	interval
O	1617	1618	[
O	1618	1620	CI
O	1620	1621	]
O	1621	1622	,
O	1623	1624	1
O	1624	1625	.
O	1625	1628	277
O	1628	1629	-
O	1629	1631	24
O	1631	1632	.
O	1632	1635	673
O	1635	1636	)
O	1637	1640	and
O	1641	1644	new
B-Symptom	1645	1652	atrophy
O	1653	1658	onset
O	1659	1661	at
O	1662	1665	FUL
O	1666	1667	(
O	1667	1669	OR
O	1669	1670	,
O	1671	1672	7
O	1672	1673	.
O	1673	1676	005
O	1676	1677	;
O	1678	1680	95
O	1680	1681	%
O	1682	1684	CI
O	1684	1685	,
O	1686	1687	2
O	1687	1688	.
O	1688	1691	300
O	1691	1692	-
O	1692	1694	21
O	1694	1695	.
O	1695	1698	337
O	1698	1699	)
O	1699	1700	.

O	1701	1708	Lesions
O	1709	1713	with
O	1714	1717	the
O	1718	1726	presence
O	1727	1729	of
B-Symptom	1730	1733	HRF
O	1734	1738	were
O	1739	1750	significant
O	1751	1761	predictors
O	1762	1764	of
O	1765	1768	new
B-Symptom	1769	1776	atrophy
O	1777	1782	onset
O	1783	1785	at
O	1786	1787	6
O	1788	1794	months
O	1795	1796	(
O	1796	1798	OR
O	1798	1799	,
O	1800	1802	30
O	1802	1803	.
O	1803	1806	161
O	1806	1807	;
O	1808	1810	95
O	1810	1811	%
O	1812	1814	CI
O	1814	1815	,
O	1816	1817	4
O	1817	1818	.
O	1818	1821	766
O	1821	1822	-
O	1822	1825	190
O	1825	1826	.
O	1826	1829	860
O	1829	1830	)
O	1831	1834	and
O	1835	1838	FUL
O	1839	1840	(
O	1840	1842	OR
O	1842	1843	,
O	1844	1846	11
O	1846	1847	.
O	1847	1850	211
O	1850	1851	;
O	1852	1854	95
O	1854	1855	%
O	1856	1858	CI
O	1858	1859	,
O	1860	1861	2
O	1861	1862	.
O	1862	1865	513
O	1865	1866	-
O	1866	1868	50
O	1868	1869	.
O	1869	1872	019
O	1872	1873	)
O	1873	1874	.

O	1875	1882	Lesions
O	1883	1887	with
O	1888	1889	a
O	1890	1898	baseline
O	1899	1906	maximum
O	1907	1913	height
B-Dimension	1915	1916	>
I-Dimension	1917	1919	80
I-Dimension	1920	1921	μ
I-Dimension	1921	1922	m
O	1923	1925	or
B-Characteristic	1926	1928	CT
B-Dimension	1929	1930	≤
I-Dimension	1931	1934	135
I-Dimension	1935	1936	μ
I-Dimension	1936	1937	m
O	1938	1944	showed
O	1945	1946	a
O	1947	1955	positive
O	1956	1967	association
O	1968	1972	with
O	1973	1976	the
O	1977	1980	new
B-Symptom	1981	1988	atrophy
O	1989	1994	onset
O	1995	1997	at
O	1998	2001	FUL
O	2002	2003	(
O	2003	2005	OR
O	2005	2006	,
O	2007	2008	7
O	2008	2009	.
O	2009	2012	886
O	2012	2013	;
O	2014	2016	95
O	2016	2017	%
O	2018	2020	CI
O	2020	2021	,
O	2022	2023	2
O	2023	2024	.
O	2024	2027	105
O	2027	2028	-
O	2028	2030	29
O	2030	2031	.
O	2031	2034	538
O	2035	2038	and
O	2039	2041	OR
O	2041	2042	,
O	2043	2044	3
O	2044	2045	.
O	2045	2048	796
O	2048	2049	;
O	2050	2052	95
O	2052	2053	%
O	2054	2056	CI
O	2056	2057	,
O	2058	2059	1
O	2059	2060	.
O	2060	2063	154
O	2063	2064	-
O	2064	2066	12
O	2066	2067	.
O	2067	2070	481
O	2070	2071	,
O	2072	2084	respectively
O	2084	2085	)
O	2085	2086	.

O	2087	2090	The
O	2091	2099	presence
O	2100	2102	of
B-Symptom	2103	2106	HRF
I-Symptom	2107	2116	overlying
I-Symptom	2117	2120	DLs
O	2120	2121	,
O	2122	2123	a
O	2124	2137	heterogeneous
O	2138	2146	internal
O	2147	2159	reflectivity
O	2160	2162	of
O	2163	2168	these
O	2169	2176	lesions
O	2176	2177	,
O	2178	2181	was
O	2182	2187	found
O	2188	2200	consistently
O	2201	2203	to
O	2204	2206	be
O	2207	2217	predictive
O	2218	2220	of
O	2221	2226	local
B-Symptom	2227	2234	atrophy
O	2235	2240	onset
O	2241	2243	in
O	2244	2247	the
O	2248	2255	ensuing
O	2256	2262	months
O	2262	2263	.

O	2264	2269	These
O	2270	2278	findings
O	2279	2286	provide
O	2287	2294	further
O	2295	2302	insight
O	2303	2307	into
O	2308	2311	the
O	2312	2319	natural
O	2320	2327	history
O	2328	2330	of
O	2331	2339	anatomic
O	2340	2346	change
O	2347	2356	occurring
O	2357	2359	in
O	2360	2368	patients
O	2369	2373	with
B-Disease	2374	2380	NNVAMD
O	2380	2381	.
